ABSTRACT
The preparation and antifungal properties of cis-1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl-methyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine (I) are described. Ketoconazole has, at low oral doses, a high in vivi activity against vaginal candidosis in rats and against cutaneous candidosis in guinea pigs.
Subject(s)
Antifungal Agents/chemical synthesis , Imidazoles/chemical synthesis , Piperazines/chemical synthesis , Animals , Candidiasis/drug therapy , Chemical Phenomena , Chemistry , Female , Guinea Pigs , Imidazoles/pharmacology , Imidazoles/therapeutic use , Miconazole/therapeutic use , Piperazines/pharmacology , RatsABSTRACT
Synthesis of 1-[2-(arylalkyl)-2-phenylethyl]-1H-imidazoles was accomplished starting from the corresponding phenylacetonitriles. Via successive alkylation, conversion to the corresponding ester, and sodium borohydride-lithium iodide reduction, beta-phenylalcanols were obtained. These alcohols were mesylated and then refluxed with imidazole in dimethylformamide to yield the title compounds, which were active in vitro against dermatophytes, yeasts, other fungi, and gram-positive bacteria. Some were also active in vivo against Candida albicans.
